Phase Zero is TBM’s four-step diagnostic for private equity portfolio companies. In a few weeks it identifies and sizes the value creation levers in a business: operational improvement, revenue growth, cost optimisation and margin expansion. The result is a fact-based roadmap, ready before the 100-day plan commits the company to a direction.
Most 100-day plans are written before anyone has properly tested what’s driving performance. Phase Zero fills that gap. It runs first, so the plan starts from evidence and not from assumptions.
In the first half of 2026, manufacturing deal value was at its lowest level for any first half since 2020. With exits slower, returns increasingly have to come from inside the portfolio company.
Even so, many 100-day plans still rest on instinct. When one of those instincts turns out to be wrong, the business loses weeks of its hold period chasing it. Phase Zero replaces that guesswork with a ranked list of levers, each with a dollar value attached, so the team knows where to act before the plan is written.
“You don’t need three months to test a hunch about what’s broken.”
Many advisers hand over a report and leave the portfolio company’s team to deliver it. TBM stays for the diagnosis and the implementation. We connect operational improvement to revenue growth, cost optimisation and margin expansion, and measure progress against the 100-day milestones. Learn more about TBM’s Private Equity Practice.
Complete the form to the right to access the full Phase Zero playbook to see how a data-driven private equity 100-day plan, anchored in the proven value creation levers private equity applies, accelerates results and de-risks execution from day one.

Download

Don’t miss industry expert insights.
Join a community committed to excellence.